Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act. The EU Artificial Intelligence (AI ...

The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

The Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) was terminated in April. After sweeping cuts ...

US President Donald Trump has resurrected a drug pricing plan that equates to International Reference Pricing.

The FDA approved 19 biosimilars in 2024, a sharp jump from the five greenlit by the agency in 2023. 2024 saw the highest ...

The executive order instructs the FDA to expedite the approval process for domestic pharmaceutical manufacturing facilities.

The US Food and Drug Administration has granted approval to Amneal Pharmaceuticals’ Brekiya (dihydroergotamine (DHE) mesylate ...

Pathos AI has raised $365m in a Series D funding round to widen its AI-enabled platform to advance the development of ...

Artificial Intelligence (AI) is now used throughout clinical trials, from recruitment to analysis – but are regulators ...

AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to ...

Boehringer Ingelheim has entered a multi-year partnership with Tempus AI to progress its cancer treatment pipeline.

The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.